{"id":"cetrorelix-and-leuprolide","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetrorelix is a GnRH antagonist that rapidly suppresses luteinizing hormone (LH) secretion, while leuprolide is a GnRH agonist that causes initial stimulation followed by downregulation of the pituitary. Together, they prevent the natural LH surge that would otherwise trigger ovulation prematurely during in vitro fertilization (IVF) cycles, allowing controlled egg retrieval.","oneSentence":"Cetrorelix and leuprolide work together to suppress the pituitary-gonadal axis by blocking GnRH signaling, preventing premature luteinizing hormone surge during controlled ovarian hyperstimulation for assisted reproduction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:20.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF)"},{"name":"Prevention of premature luteinizing hormone surge during fertility treatment"}]},"trialDetails":[{"nctId":"NCT04094467","phase":"PHASE4","title":"Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-12-07","conditions":"Polycystic Ovary Syndrome","enrollment":150},{"nctId":"NCT01669291","phase":"NA","title":"Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation","status":"COMPLETED","sponsor":"Main Line Fertility Center","startDate":"2012-07","conditions":"Fertility","enrollment":43},{"nctId":"NCT01948804","phase":"PHASE4","title":"The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.","status":"UNKNOWN","sponsor":"Pınar Özcan Cenksoy","startDate":"2014-01","conditions":"Poor Responders Undergoing IVF","enrollment":100},{"nctId":"NCT00883766","phase":"NA","title":"Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1","status":"TERMINATED","sponsor":"Fundacion Dexeus","startDate":"2009-04","conditions":"Polycystic Ovary Syndrome, In Vitro Fertilization","enrollment":172},{"nctId":"NCT01595334","phase":"NA","title":"Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity","status":"UNKNOWN","sponsor":"Southern Cross Fertility Centre","startDate":"2012-04","conditions":"Infertility","enrollment":300},{"nctId":"NCT00505817","phase":"PHASE4","title":"GnRH Agonist and Antagonists in an Oocyte Donation Program","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"","conditions":"Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cetrorelix and Leuprolide","genericName":"Cetrorelix and Leuprolide","companyName":"Instituto Valenciano de Infertilidad, IVI VALENCIA","companyId":"instituto-valenciano-de-infertilidad-ivi-valencia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetrorelix and leuprolide work together to suppress the pituitary-gonadal axis by blocking GnRH signaling, preventing premature luteinizing hormone surge during controlled ovarian hyperstimulation for assisted reproduction. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF), Prevention of premature luteinizing hormone surge during fertility treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}